StockData
Enanta Pharmaceuticals Inc logo

Enanta Pharmaceuticals Inc (ENTA) stock

ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-K on Nov 18, 2026Score 3/303% below fair value
$8.23−0.46 (-5.29%)

Close on Nov 18, 2026Market cap $239.70MP/E –Yield –

Enanta Pharmaceuticals pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Enanta Pharmaceuticals's pe ratio was 545.4× on Oct 30, 2020, against 19.8× a year earlier. Over the last 5 years it ranged from 6.3× to 652.4×, with a median of 22.7×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2020Oct 30, 2020545.4×+517.4
2019Dec 31, 201928.0×+7.6
2018Dec 31, 201820.4×−44.1
2017Dec 29, 201764.5×+34.8
2016Dec 30, 201629.6×+21.6
2015Dec 31, 20158.1×−20.2
2014Dec 31, 201428.3×−22.6
2013Dec 31, 201350.8×–

More Enanta Pharmaceuticals figures

See a number that looks wrong?